StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $44.10 | $53.13 | +20.48% | 6.9M |
| 05-12 | $53.80 | $56.60 | +5.20% | 3.9M |
| 05-13 | $56.00 | $57.59 | +2.84% | 2.3M |
| 05-14 | $57.63 | $59.30 | +2.90% | 1.6M |
| 05-15 | $57.74 | $56.93 | -1.40% | 2.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for LQDA.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for LQDA.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $132.87M | $158.32M | $66.30M | $11.96M |
Operating Income | $61.50M | $-51.38M | $-71.16M | $-72.93M |
Net Income | $52.86M | $-68.92M | $-83.48M | $-41.58M |
EPS (Diluted) | $0.52 | $-0.80 | $-0.97 | $-0.94 |
Total Assets | $401.53M | $327.93M | $275.98M | $257.41M |
Total Liabilities | $292.95M | $283.19M | $253.93M | $242.22M |
Cash & Equivalents | $222.79M | $190.68M | $157.50M | $173.42M |
Free Cash Flow OCF − CapEx | $50.16M | $-40.02M | $-82.23M | $-71.55M |
Shares Outstanding | 88.31M | 87.20M | 86.82M | 85.86M |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.